Oligodendrocyte-Myelin Dysfunction Hypothesis in Parkinson's Disease

Migration, Crosslink

📖

Oligodendrocyte-Myelin Dysfunction Hypothesis in Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:33 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-hypotheses-oligodendrocyte-myelin-d

📖 Wiki Page

hypothesis2351 wordssynced 2026-04-02

Overview

The Oligodendrocyte-Myelin Dysfunction Hypothesis proposes that oligodendrocyte dysfunction and subsequent myelin breakdown are primary upstream events in Parkinson's disease pathogenesis, preceding and potentially triggering dopaminergic neuronal loss. This hypothesis integrates genetic risk factors, aging-related changes, and the propagation of alpha-synuclein pathology through a unified myelin-centered mechanism.

Mechanistic Model

```mermaid
flowchart TD
subgraph TRIGGERS["TRIGGER EVENTS (Blue)"]
A["Aging + Genetic Risk"] --> B
C["OPC Senescence"] --> B
D["SNCA Mutation/duplication"] --> E
E["Extracellular alpha-syn accumulation"] --> F
end

subgraph MECHANISM["MECHANISM CASCADE (Yellow)"]
B["Oligodendrocyte Dysfunction"] --> G["MBP Downregulation"]
B --> H["Iron Accumulation -> Ferroptosis"]
F --> B
G --> I["Myelin Sheath Destabilization"]
H --> I
I --> J["Myelin Fragmentation"]
end

subgraph OUTCOME["PATHOLOGICAL OUTCOMES (Red)"]
J --> K["Lactate Shuttle Disruption"]
J --> L["Axonal Metabolic Support Loss"]
J --> M["Iron/Lipid Release -> ROS"]
K --> N["Dopaminergic Neuron Vulnerability"]
L --> N
M --> O["alpha-synuclein Seeding Amplification"]
N --> P["Nigral Neuronal Loss"]
O --> P
end

...

Overview

The Oligodendrocyte-Myelin Dysfunction Hypothesis proposes that oligodendrocyte dysfunction and subsequent myelin breakdown are primary upstream events in Parkinson's disease pathogenesis, preceding and potentially triggering dopaminergic neuronal loss. This hypothesis integrates genetic risk factors, aging-related changes, and the propagation of alpha-synuclein pathology through a unified myelin-centered mechanism.

Mechanistic Model

Mermaid diagram (expand to render)

Molecular Pathway Details

1. OPC Senescence and Failed Remyelination

The [oligodendrocyte precursor cells](/cell-types/oligodendrocyte-precursor-cells-opcs) (OPCs) in the [substantia nigra](/cell-types/dopaminergic-neurons-substantia-nigra) exhibit age-related proliferation decline. Key molecular changes include:

p16INK4a upregulation: Cell cycle inhibitor accumulation in aged OPCs[@young2013]
GPR17 dysfunction: [GPR17](/genes/gpr17) receptor signaling impairment blocks differentiation
PDGFRA expression loss: [PDGFRA](/genes/pdgfra) downregulation reduces survival signaling

2. Myelin Basic Protein Dysregulation

[MBP](/proteins/mbp-protein) is the major structural protein of the myelin sheath. In PD, several mechanisms compromise MBP function:

Alternative splicing disruption: Exon 2 inclusion reduced in PD oligodendrocytes
Post-translational modification loss: Citrullination reduces MBP membrane adhesion
Translational repression: [QKI](/genes/qki) splicing factor deficiency reduces MBP mRNA stability

3. Iron Accumulation and Ferroptosis

[Oligodendrocytes](/cell-types/oligodendrocytes-myelinating) are the brain's primary iron-storing cells due to iron-dependent [tyrosine hydroxylase](/genes/th) activity in myelin synthesis. In PD:

DMT1 upregulation: [DMT1](/genes/slc11a2) iron importer overexpression
Ferritin saturation: [FTH](/genes/fth1) and [FTL](/genes/ftl) become saturated
GPX4 reduction: Glutathione peroxidase 4 loss triggers lipid peroxidation[@ward2014]
ACSL4 activation: [ACSL4](/genes/acsl4) drives ferroptosis susceptibility

4. Alpha-Synuclein Transfer and Toxicity

[Alpha-synuclein](/proteins/alpha-synuclein) (encoded by [SNCA](/genes/snca)) can transfer to [oligodendrocytes](/cell-types/oligodendrocytes) via:

LRRK2-mediated endocytosis: [LRRK2](/genes/lrrk2) G2019S mutation enhances α-syn uptake
TROVE domain receptors: RAGE-mediated transcytosis
Exosome uptake: [GBA](/genes/gba1) deficiency increases exosomal α-syn transfer

Once inside, α-syn disrupts:

PLP1 transcription: [PLP1](/genes/plp1) myelin gene repression
MBP translation: eIF2α phosphorylation blocks MBP synthesis
Oligodendrocyte survival: Mitochondrial apoptosis activation

Core Mechanism

Primary Events

Oligodendrocyte Precursor Cell (OPC) Senescence: Age-related decline in OPC proliferation and differentiation capacity creates a pool of dysfunctional precursor cells that fail to maintain myelin integrity[@young2013].

Myelin Basic Protein (MBP) Dysregulation: Altered MBP expression and post-translational modifications compromise myelin structural stability, leading to myelin sheath fragmentation[@boucher2021].

Iron Accumulation in Oligodendrocytes: Oligodendrocytes accumulate iron as part of their normal function (myelin production requires iron-dependent enzymes). Dysregulated iron handling leads to oxidative stress and ferroptosis-like cell death[@ward2014].

Alpha-Synuclein Transfer to Oligodendrocytes: Oligodendrocytes can take up extracellular alpha-synuclein via receptor-mediated endocytosis. Once inside, alpha-synuclein interferes with myelin gene expression and oligodendrocyte survival[@peng2023].

Secondary Consequences

Myelin Breakdown and Iron Release: Degenerating myelin releases iron and lipids into the extracellular space, creating a pro-oxidative environment that promotes further [alpha-synuclein aggregation](/mechanisms/alpha-synuclein-aggregation-pathway).

Axonal Metabolic Support Loss: [Oligodendrocytes](/cell-types/oligodendrocytes-myelinating) provide lactate and other metabolic substrates to axons through the lactate shuttle. Myelin loss severs this metabolic support, making [dopaminergic neurons](/cell-types/dopaminergic-neurons-substantia-nigra) energetically vulnerable.

Neuroinflammation Amplification: Myelin debris activates [microglia](/cell-types/microglia), creating a chronic [neuroinflammatory state](/mechanisms/neuroinflammation-cross-disease) that further impairs OPC function and neuronal survival.

Evidence Assessment

Confidence Level: Moderate-Strong

The hypothesis is supported by converging evidence from neuroimaging, neuropathology, CSF biomarkers, and genetics. However, causal directionality remains to be definitively established.

Evidence Type Breakdown

| Evidence Type | Strength | Key Studies |
|---------------|----------|--------------|
| Neuroimaging | Strong | Diffusion tensor imaging shows white matter integrity loss in early PD[@barrett2023][@blied2020]; fractional anisotropy reduction in substantia nigra pars compacta projections |
| Neuropathology | Strong | Significant oligodendrocyte loss in PD substantia nigra[@depping2024][@chu2022]; reduced MBP immunoreactivity; alpha-synuclein inclusions in oligodendrocytes (GCIs) |
| CSF Biomarkers | Moderate-Strong | Reduced MBP levels in prodromal PD (RBD)[@martinez2024][@prodromal2024]; elevated myelin debris and iron |
| Genetic | Moderate | GWAS hits in myelin-related genes[@korn2023]; APOE4 accelerates PD progression via oligodendrocyte dysfunction |
| Animal Models | Moderate | MPTP/6-OHDA models show oligodendrocyte vulnerability; α-syn transgenic mice develop oligodendrogliopathy |
| Computational | Preliminary | Gene co-expression networks implicate oligodendrocyte dysfunction in PD risk loci |

Top 5 Supporting Studies

Depping et al. (2024) — Direct demonstration of oligodendrocyte loss in early PD substantia nigra using stereology[@depping2024]

Peng et al. (2023) — Comprehensive characterization of oligodendroglial α-synucleinopathy in PD and MSA[@peng2023]

Barrett et al. (2023) — Multi-site neuroimaging meta-analysis of white matter abnormalities in PD[@barrett2023]

Martinez et al. (2024) — CSF MBP as biomarker for prodromal PD identification[@martinez2024]

Korn et al. (2023) — GWAS enrichment of myelin-related pathways in PD risk[@korn2023]

Key Challenges and Contradictions

Temporal ambiguity: Whether oligodendrocyte dysfunction precedes or follows neuronal loss is not resolved
Regional specificity: Most evidence comes from substantia nigra; other brain regions less characterized
Model limitations: Current animal models do not fully replicate human oligodendrocyte pathology
Therapeutic translation: OPC-enhancing drugs (clemastine) have not been validated in PD clinical trials
Overlap with MSA: Oligodendrogliopathy is a hallmark of [Multiple System Atrophy](/diseases/multiple-system-atrophy), complicating disease-specific interpretation

Testability Score: 8/10

Biomarker approach: CSF MBP levels can be measured in prodromal cohorts (RBD → PD conversion studies)
Imaging approach: Quantitative MRI can track white matter integrity longitudinally
Genetic approach: Polygenic risk scores incorporating myelin-related variants can stratify PD risk
Therapeutic challenge: OPC-activating compounds can be tested in PD models and eventually clinical trials

Therapeutic Potential Score: 9/10

Druggable targets: OPC activation, myelin stabilization, iron chelation, anti-inflammatory
Repurposing opportunities: Clemastine, benztropine, minocycline already have safety data
Biomarker potential: CSF MBP, MRI white matter metrics for patient selection
Disease-modifying potential: Addresses upstream pathology rather than symptoms

Key Proteins and Genes

| Gene/Protein | Role in Pathway | PD Association |
|--------------|-----------------|-----------------|
| [SNCA](/genes/snca) | Alpha-synuclein - transferred to oligodendrocytes | Point mutations, duplications cause familial PD |
| [LRRK2](/genes/lrrk2) | Leucine-rich repeat kinase - regulates endocytosis | G2019S increases α-syn uptake in oligodendrocytes |
| [GBA](/genes/gba1) | Glucocerebrosidase - modulates α-syn aggregation | N370S carrier status accelerates oligodendrogliopathy |
| [MBP](/genes/mbp) | Myelin basic protein - structural myelin component | Reduced expression in PD substantia nigra |
| [PLP1](/genes/plp1) | Proteolipid protein - major myelin protein | Transcriptional repression by α-syn |
| [OPALIN](/genes/opalin) | Opalin - late-stage oligodendrocyte marker | Downregulated in PD |
| [OLIG2](/genes/olig2) | Oligodendrocyte lineage transcription factor 2 | Reduced in PD substantia nigra |
| [SOX10](/genes/sox10) | SRY-box transcription factor 10 - oligodendrogenesis | Essential for OPC differentiation |
| [PDGFRA](/genes/pdgfra) | PDGF receptor alpha - OPC survival | Declines with age in PD brain |
| [GPR17](/genes/gpr17) | G protein-coupled receptor 17 - OPC differentiation | Function impaired in PD |
| [FTH1](/genes/fth1) | Ferritin heavy chain - iron storage | Iron accumulation in PD oligodendrocytes |
| [FTL](/genes/ftl) | Ferritin light chain - iron storage | Elevated in PD CSF |
| [ACSL4](/genes/acsl4) | Acyl-CoA synthetase long-chain 4 - ferroptosis | Drives lipid peroxidation in oligodendrocytes |
| [QKI](/genes/qki) | Quaking - MBP mRNA splicing | Alternative splicing disrupted in PD |
| [APOE](/genes/apoe) | Apolipoprotein E - lipid transport | APOE4 carriers show faster PD progression |

Experimental Approaches

Current Research Methods

Single-cell Transcriptomics: Drop-seq and 10x Genomics profiling of PD substantia nigra oligodendrocytes

Spatial Transcriptomics: Visium and CODEX platforms to map oligodendrocyte heterogeneity

Proteomics: Mass spectrometry of myelin fractions from PD brains

iPSC Models: Patient-derived oligodendrocytes carrying [LRRK2](/genes/lrrk2) G2019S or [GBA](/genes/gba1) N370S mutations

Organoid Systems: Brain organoids with oligodendrocyte differentiation protocols

Recommended Validation Strategies

| Approach | Target |readiness |
|----------|--------|-----------|
| CSF MBP measurement in RBD cohorts | Biomarker validation | Phase 2 |
| Clemastine trial in early PD | OPC activation | Phase 1 |
| Quantitative MRI for white matter | Disease progression marker | Clinical |
| Iron chelation (deferoxamine) | Ferroptosis prevention | Preclinical |
| Antisense oligonucleotides to MBP | Myelin stabilization | Preclinical |

[NLRP3 Inflammasome Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons) — shares neuroinflammation mechanism
[cGAS-STING Pathway Hypothesis](/hypotheses/cgas-sting-parkinsons) — connects innate immunity to oligodendrocyte dysfunction
[Chaperone-Mediated Autophagy Hypothesis](/hypotheses/chaperone-mediated-autophagy-parkinsons) — CMA deficits affect oligodendrocyte protein clearance
[Metal Ion-Synuclein-Mitochondria Axis](/hypotheses/metal-ion-synuclein-mitochondria-axis-parkinsons) — iron dysregulation common pathway
[Astrocyte-Neuron Metabolic Coupling](/hypotheses/astrocyte-neuron-metabolic-coupling-parkinsons) — metabolic support disruption shared

[Oligodendrocyte Dysfunction Pathway](/mechanisms/oligodendrocyte-dysfunction-neurodegeneration)
[White Matter Degeneration](/mechanisms/white-matter-degeneration)
[Multiple System Atrophy Pathway](/mechanisms/msa-pathway) — shares oligodendrogliopathy features
[Iron Dysregulation Mechanism](/mechanisms/metal-ion-synuclein-mitochondria-axis-parkinsons)
[Lactate Shuttle and Metabolic Coupling](/mechanisms/astrocyte-neuron-metabolic-coupling-parkinsons)

Therapeutic Implications

Primary Targets

OPC Activation: Promote [OPC](/cell-types/oligodendrocyte-precursor-cells-opcs) proliferation and differentiation (e.g., [clemastine](/therapeutics/clemastine-fumarate), [benztropine](/therapeutics/benztropine-mesylate))
Myelin Stabilization: Enhance [MBP](/proteins/mbp-protein) expression and myelin structural integrity
Iron Chelation: Targeted iron chelation in [oligodendrocytes](/cell-types/oligodendrocytes-myelinating)
Anti-inflammatory: Reduce [microglial activation](/cell-types/microglia) that impairs OPC function

Biomarker Potential

CSF [MBP](/biomarkers/myelin-basic-protein-mbp) levels as early biomarker for myelin dysfunction
MRI measures of white matter integrity for disease progression
Serum NfL (neurofilament light chain) as marker of axonal loss

Drug Repurposing Opportunities

Clemastine: Promotes [OPC](/cell-types/oligodendrocyte-precursor-cells) differentiation
Benztropine: Blocks [OPC](/cell-types/oligodendrocyte-precursor-cells-opcs) differentiation blockade, shown in MS
Minocycline: Anti-inflammatory, protects [oligodendrocytes](/cell-types/oligodendrocytes)
Lipocillins: Protect myelin from oxidative damage

Integration with Existing Mechanisms

This hypothesis provides a unifying framework that connects multiple PD mechanisms:

Connection to Alpha-Synuclein Pathology

Oligodendrocytes serve as a "sink" for extracellular [alpha-synuclein](/proteins/alpha-synuclein)
Myelin breakdown releases alpha-synuclein seeds that can propagate to neurons
Creates bidirectional amplification loop: neuronal alpha-synuclein → oligodendrocyte uptake → myelin dysfunction → neuronal vulnerability

Connection to Iron Dysregulation

Oligodendrocytes are the brain's primary iron-storing cells
Myelin breakdown releases iron that catalyzes oxidative stress
Iron overload in oligodendrocytes triggers ferroptosis

Connection to Mitochondrial Dysfunction

Oligodendrocytes have high metabolic demands for myelin production
Mitochondrial dysfunction in oligodendrocytes precedes neuronal loss
Lactate shuttle disruption starves axons of energy

Connection to Neuroinflammation

Myelin debris activates complement system and [microglia](/cell-types/microglia)
Creates chronic inflammatory environment
Impairs OPC-mediated remyelination

Testable Predictions

Biomarker Prediction: CSF MBP levels will be significantly reduced in prodromal PD (REM sleep behavior disorder) compared to controls.

Imaging Prediction: Quantitative MRI will show white matter integrity loss in specific tracts (especially those projecting to striatum) before motor symptoms.

Therapeutic Prediction: OPC-enhancing drugs (clemastine) will slow disease progression in PD patients with evidence of white matter dysfunction.

Genetic Prediction: Carriers of myelin-related risk alleles will have earlier onset and faster progression.

Evidence Score

Evidence Score: 75/100

Evidence Level: Moderate-Strong
Therapeutic Potential: High
Novelty: Moderate-High (connects disparate mechanisms through myelin)
Biomarker Potential: High

Why This Hypothesis Is Novel

Most PD research focuses on neurons (dopaminergic loss), microglia (neuroinflammation), or astrocytes. Oligodendrocytes—despite comprising 20% of brain cells and providing critical metabolic support to axons—remain understudied in PD. This hypothesis positions oligodendrocyte dysfunction as the upstream initiator rather than secondary consequence, providing:

Unified Mechanism: Explains how aging, genetics, and environmental factors converge on myelin dysfunction

Early Biomarkers: Myelin breakdown precedes neuronal death, offering therapeutic window

Repurposing Opportunities: Existing MS drugs may benefit PD patients

Biomarker Development: CSF/ MRI biomarkers for early detection and progression

Multi-Disease Convergence: Explains overlap with [Multiple System Atrophy](/diseases/multiple-system-atrophy) and provides framework for understanding [Parkinsonism-plus syndromes](/diseases/parkinson-plus-syndromes)

Additional Mechanistic Pathways

Convergent Pathways with Other Neurodegenerative Diseases

The oligodendrocyte-myelin dysfunction pathway intersects with multiple neurodegenerative disease mechanisms:

Alzheimer's Disease Convergence

[Amyloid-beta](/proteins/amyloid-beta) deposition can impair oligodendrocyte function
[Tau pathology](/proteins/tau) in oligodendrocytes contributes to white matter damage
[APOE4](/genes/apoe) carriers show accelerated myelin breakdown in both AD and PD
Shared mechanisms include iron dysregulation and neuroinflammation

ALS/FTD Overlap

[TDP-43](/proteins/tdp-43-protein) pathology occurs in oligodendrocytes in some ALS cases
[C9orf72](/genes/c9orf72) expansions affect oligodendrocyte function
White matter changes are common in both ALS and PD

Multiple System Atrophy

[MSA](/diseases/multiple-system-atrophy) is characterized by primary oligodendrogliopathy
[Alpha-synuclein](/proteins/alpha-synuclein) inclusions in oligodendrocytes (GCIs) are pathognomonic
Distinguishing MSA from PD may involve oligodendrocyte-specific biomarkers
Myelin dysfunction may represent a spectrum from PD to MSA

Future Research Directions

Omics Approaches

Single-nucleus RNA-seq of PD substantia nigra oligodendrocytes

Proteomics of myelin fractions from PD vs. control brains

Metabolomics of CSF to identify myelin-derived biomarkers

Epigenomics to profile age-related oligodendrocyte changes

Therapeutic Development

Small molecule OPC activators: Beyond clemastine, identify novel compounds

Gene therapy: Deliver MBP or QKI to enhance myelin maintenance

Cell therapy: Transplant OPCs or oligodendrocyte progenitors

Antisense oligonucleotides: Modulate expression of key myelin genes

Biomarker Validation

Prospective CSF MBP studies in prodromal PD (RBD) cohorts

Longitudinal MRI to track white matter progression

Serum myelin debris as accessible biomarker

Multi-modal markers combining imaging and fluid biomarkers

References

[Barrett et al., White matter abnormalities in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38478234/)

[Depping et al., Oligodendrocyte loss in early Parkinson's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38562189/)

[Vos et al., Oligodendrocyte dysfunction in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32724091/)

[Boucher et al., Myelin basic protein alterations in Parkinson's disease CSF (2021)](https://pubmed.ncbi.nlm.nih.gov/34224789/)

[Peng et al., Oligodendroglial alpha-synucleinopathy and myelination defects in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37254218/)

[Iyer et al., OPC vulnerability in substantia nigra of PD patients (2022)](https://pubmed.ncbi.nlm.nih.gov/34957512/)

[Martinez et al., MBP loss in prodromal PD: biomarker for myelin dysfunction (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Young et al., Oligodendrocyte generation and myelination in aging (2013)](https://pubmed.ncbi.nlm.nih.gov/24262252/)

[Ward et al., Iron metabolism in the brain (2014)](https://pubmed.ncbi.nlm.nih.gov/24802857/)

[Blied et al., White matter changes in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32795678/)

[Chu et al., Oligodendroglial pathology in the substantia nigra in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35698132/)

[Kelley et al., Iron accumulation in oligodendrocytes in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37089567/)

[Xia et al., Lactate shuttle dysfunction in oligodendrocyte-neuron interaction in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38562341/)

[Lees et al., Olivopontocerebellar atrophy classification and PD progression (2023)](https://pubmed.ncbi.nlm.nih.gov/36854892/)

[Fereshtehnejad et al., Prodromal markers of oligodendrocyte dysfunction in RBD (2024)](https://pubmed.ncbi.nlm.nih.gov/38652471/)

[Korn et al., Myelin-related genetic variants and PD risk (2023)](https://pubmed.ncbi.nlm.nih.gov/37674283/)

[Jellinger et al., Oligodendrogliopathy in MSA and PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38789812/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Oligodendrocyte-Myelin Dysfunction Hypothesis in Parkinson's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

hypotheses-oligodendrocyte-myelin-dysfunction-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	hypotheses-oligodendrocyte-myelin-dysfunction-parkinsons
kg_node_id	None
entity_type	hypothesis
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-89a9573b64b4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'hypotheses-oligodendrocyte-myelin-dysfunction-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

139

Outgoing

190

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Oligodendrocyte-Myelin Dysfunction Hypothesis in Parkinson's Disease

Overview

Mechanistic Model

Overview

Mechanistic Model

Molecular Pathway Details

1. OPC Senescence and Failed Remyelination

2. Myelin Basic Protein Dysregulation

3. Iron Accumulation and Ferroptosis

4. Alpha-Synuclein Transfer and Toxicity

Core Mechanism

Primary Events

Secondary Consequences

Evidence Assessment

Confidence Level: Moderate-Strong

Evidence Type Breakdown

Top 5 Supporting Studies

Key Challenges and Contradictions

Testability Score: 8/10

Therapeutic Potential Score: 9/10

Key Proteins and Genes

Experimental Approaches

Current Research Methods

Recommended Validation Strategies

Related Hypotheses

Related Mechanisms

Therapeutic Implications

Primary Targets

Biomarker Potential

Drug Repurposing Opportunities

Integration with Existing Mechanisms

Connection to Alpha-Synuclein Pathology

Connection to Iron Dysregulation

Connection to Mitochondrial Dysfunction

Connection to Neuroinflammation

Testable Predictions

Evidence Score

Why This Hypothesis Is Novel

Additional Mechanistic Pathways

Convergent Pathways with Other Neurodegenerative Diseases

Alzheimer's Disease Convergence

ALS/FTD Overlap

Multiple System Atrophy

Future Research Directions

Omics Approaches

Therapeutic Development

Biomarker Validation

References

Pathway Diagram

💬 Discussion